| Parameters | Description |
|---|---|
| Category of Drug | Etoposide is Immunosuppressives Drug |
| Mechanism of Action 1 | Etoposide inhibits DNA topoisomerase II, causing inhibition of DNA re-ligation. This interferes with DNA synthesis and can lead to apoptosis of the cancer cell. |
| Chemical Structure 2 |  |
| Molecular Details | Molecular Formula: C29H32O13 Molecular Weight: 588.6 g/mol |
| IUPAC Name | (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one |
| Indications | Etoposide is used for 1. Refractory testicular tumors 2. Acute leukemia 3. Malignant lymphoma 4. lung cancer |
| Well Known Pharmaceutical Brands | Posid- Cadila |
| Available dosage forms | 1. CAPSULES 2. INJECTION  |
| Dose | Adult- Initially 50 to 100 mg/m2, body surface area daily by infusing over 30 to 60 min |
| Pharmacokinetic properties | 1. Peak plasma concentration-1-1.5 hrs. 2. Mean bioavailability- 50% (range of 25% – 75%). 3. Volume of distribution= 18 – 29 L. 4. Protein binding- 97% 5. Metabolism- 40% excreted unchanged in the urine 6. Half-life- 4-11 hours |
| Contraindications | 1. Hypersensitivity 2. Severe liver dysfunction 3. Pregnancy 4. lactation |
| Precautions | 1. Hepatic impairment 2. Interactions 3. Renal impairment |
| Adverse Effects | 1. Alopecia 2. Gastrointestinal disturbances 3. Thrombophlebitis 4. Neuritis |
| Pregnancy Category | D |
Check the other Antineoplastic and Immunosuppressive agents:
Pingback: 5-Fluorouracil- How does it act? What is the drug profile? - PharmaCampus